Silence Therapeutics (SLN) Share-based Compensation (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 30.88% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (down 55.62% YoY), and the FY2025 full-year result was $8.1 million, down 72.25% from the prior year.
• Share-based Compensation advanced to $2.4 million in Q1 2026, from -$86000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2024 to a low of -$86000.0 in Q4 2025.
• A 3-year average of $3.0 million and a median of $3.5 million in 2025 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 14.04% in 2025, while the deepest fall reached 102.16% in 2025.
• Tracing SLN's Share-based Compensation over 3 years: stood at $4.0 million in 2024, then slumped by 102.16% to -$86000.0 in 2025, then soared by 2945.35% to $2.4 million in 2026.
• Business Quant data shows SLN's Share-based Compensation at $2.4 million in Q1 2026, -$86000.0 in Q4 2025, and $2.5 million in Q3 2025.